Strategic Cannabis Acquisition Complete: MXC Set to Break Ground in Europe, Australia the Next Step

Feb 23, 2017

In the case of MGC Pharmaceuticals (ASX: MXC), this ASX-dwelling green thumb is making a bee-line for the global medical cannabis market. This most recent move by the Australian government opens up several commercial channels for MXC with regard to its medical cannabis and cosmetics plays, given recent developments with its European operations.

read article

CDY Backs Hair Raising Growth for 2017 as it Capitalises on US Entry

Jan 24, 2017

Volume is a key word for life sciences play Cellmid (ASX: CDY). Its key hair loss product Evolis® aims to replace thinning hair with voluminous locks, while management seeks to volumise revenues, stock liquidity, and ultimately shareholders’ returns.

read article

A Medical Cannabis First: CPH Secures Animal Feed Product Registration

Jan 18, 2017

It has been a busy two months for Creso Pharma (ASX: CPH) since we last featured the company in November 2016 and certainly a happy new year thus far with the news that CPH recently obtained the first ever EU registration for two CBD-based animal feed nutraceutical products.

read article

MMJ Set to Unlock Value in Bullish Canadian Cannabis Market

Nov 10, 2016

If you hadn’t already heard, cannabis is currently undergoing a breath-taking liberation across the globe as doctors, clinics and government departments all gradually realise its medicinal and commercial endowments.

read article

First Cannabis Revenues in Sight for CPH

Nov 07, 2016

The medicinal cannabis industry, whilst attracting a lot of publicity, is still in its early stages as a new niche with very few current or even experienced market participants. Even the big pharma companies have so far been apprehensive towards taking significant stakes in medicinal cannabis, and have preferred to wait out the legislative rigmarole making headlines in the US, Europe and Australia.

read article

NOX Clinic Ready: Phase 1 Study Kicks off in Coming Weeks

Oct 26, 2016

Earlier this month, actor and director Ben Stiller publicised the fact he fought (and beat) an aggressive form of prostate cancer in 2014. He states his success over the oft-deadly disease is down to a PSA test that he took at an earlier age than what doctors commonly recommend.

read article

Newly Listed Medical Cannabis Stock Targets $200BN Nutraceutical Opportunity

Oct 20, 2016

The low-risk health profile of medical cannabis (MC) has finally gained enough traction to allow legislation to soften… which is why many investors have raised their binoculars on the lookout for bright medical cannabis companies at an early stage of development.

read article

Positive Phase II Results: DXB on Track to Find Kidney Disease Solution

Oct 10, 2016

There could be a light at the end of the tunnel for chronic kidney disease sufferers, suffering from a rare form of the disease known as focal segmental glomerulosclerosis (FSGS). In fact several multi-million dollar companies in the space are dedicated to delivering life changing therapies to people living with chronic kidney disease with significant unmet medical needs.

read article

MXC Expecting Imminent Medical Cannabis Revenue Deals

Oct 06, 2016

As Australia prepares for the legalisation of medicinal marijuana in November – following bipartisan support at a Federal level and a formal decision by the Therapeutic Goods Administration – the future is looking encouraging for medical cannabis company MGC Pharmaceuticals (ASX:MXC).

read article

CDY Sales Up 72%: $100M Revenue Targets in Place

Sep 14, 2016

Calendar year 2016 will go down as a dynamic period of growth in the life of Cellmid (ASX: CDY), a revenue generating life sciences company with lead programs in multiple disease indications and a consumer health business which has just come into its own in the last 12 months.

read article

Canadian Pot Stocks Light Up the TSX: Is MMJ Next?

Aug 30, 2016

While MMJ PhytoTech (ASX:MMJ) has operations all around the globe, for its growing operations it has bunkered down in Canada and already established a solid base there. There are several reasons for this: Canada has a more advanced growing industry than anywhere in the world; its TSX listed medical marijuana stocks are gaining traction on the market and regulations are well and truly opening up.

read article

ACW Starts Phase II Clinical Trials: Major Milestone Set to Unlock Value Uplift?

Aug 24, 2016

There are currently an estimated 50 million suffers of Alzheimer’s disease (AD) globally, the highest rate in history. The consequent costs on healthcare providers are enormous and growing.

read article

DXB Close to Phase 2 Results: Progresses Promising CKD Product

Aug 16, 2016

Dimerix (ASX:DXB) has just completed its “pre-IND” consultation with US regulatory body the Food and Drug Administration (FDA) with some encouraging outcomes reported. The big news for DXB is that its intended Phase 3 DMX-200 trial will be positioned as an adjunct therapy and not a fixed dose combination therapy.

read article

New ASX Listing to Turbo Charge Treatment in $100BN Oncology Market

Aug 09, 2016

The weird and wonderful world of Biotechnology has a lot going for it — an industry working at the sharp-end of breakthrough medical research, Biotech is also one of the more enticing investment landscapes of modern times. In how many other industries are companies literally striving to save lives?

read article

Medical Cannabis Stock MXC Approaching Revenue Uplift?

Jul 22, 2016

Having gained regulatory approval to sell its MGC Derma Anti-Aging line of Cannabidiol-based cosmetic products in the US, MGC Pharmaceuticals (ASX:MXC) recently received its first revenues under its exclusive Californian distribution deal. The first year of the deal is expected to net MXC approximately AU$1.76M – a substantial number for this $51.5M capped company that has only really been on the ASX boards for a short amount of time.

read article

US Sales Unlocked for CDY: Pathway to $100M Revenue in Near Term

Jul 20, 2016

After generating strong sales figures across Japan and Australia for its hair loss product evolis®, Cellmid (ASX:CDY) has now taken its first step in cracking the major US market. The global hair loss market is estimated to be around US$7BN annually, with topical treatments accounting for $2.3 billion of that market.

read article

New ASX Listing: $15M Capped Stock with Phase II Trialled Cancer Drug

Jul 19, 2016

One of the latest stocks to list on the ASX happens to have a very small market cap, but a very advanced oncology drug with early sales potential. This $15M capped stock just raised $4M as part of its entry to the ASX, and its inherent value is in a niche cancer drug named Bisantrene that was ‘lost’ in the 1990s – buried under the weight of so-called billion-dollar blockbuster drugs that better suit Big Pharma’s margins.

read article

MMJ Now Licensed to Grow Medical Cannabis

Jul 05, 2016

There are just 32 companies in Canada that have a license to grow medical cannabis – and MMJ PhytoTech, Ltd (ASX:MMJ) has just officially joined their ranks – the first ASX listed company to do so. A licence to grow medicinal cannabis is not easy to get your hands on in Canada – over 1200 companies have tried, and over 1000 have failed or given up – indicating the stringent nature of the country’s health regulators.

read article
Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.